Fosun International's 2025 Revenue Reaches RMB173.43 Billion

Fosun International reported a total revenue of RMB173.43 billion for 2025, with overseas income contributing 54.7%. Key sectors like pharmaceuticals, healthcare, and finance showed robust growth. Fosun Pharma achieved a net profit of RMB3.371 billion, marking a 21.69% increase, while Fosun Insurance Portugal saw a 15.8% rise in net profit. The company's investment in technology amounted to RMB7.8 billion, with significant progress in drug approvals and clinical trials.

Club Med, a subsidiary, recorded revenue of RMB17.97 billion, driven by increased occupancy rates and daily bed rates. Fosun adjusted its operations to focus on core businesses, leading to non-cash impairment provisions of RMB23.4 billion, reflecting revaluations in real estate and non-core assets.

Despite these adjustments, Fosun maintained a strong financial position with a debt ratio of 57%. The company aims for RMB10 billion in annual profit and plans increased dividend payouts. Fosun remains focused on sustainable growth and optimizing its business structure.